Randomized, Open-label, Multi-center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-monthly Ibandronate and Once-weekly Risedronate. A Six-month, Two-sequence, and Two-period Crossover Study

Trial Profile

Randomized, Open-label, Multi-center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-monthly Ibandronate and Once-weekly Risedronate. A Six-month, Two-sequence, and Two-period Crossover Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2015

At a glance

  • Drugs Ibandronic acid (Primary) ; Risedronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by Roche.
    • 21 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top